About us
Who are we
Founded on the principles of advancement, advocacy, and accessibility, the Association of Veterinary Vaccine Manufacturers (AVVM) is a global network of veterinary vaccine developers and manufacturers dedicated to improving animal welfare through high-quality, safe, affordable, and effective vaccines.
The demand for veterinary vaccines across poultry, cattle, and companion animal sectors underscores a critical unmet need in animal health. The role of AVVM is essential to address this gap efficiently. Such an organisation can coordinate efforts to enhance vaccine production, streamline regulatory processes, and foster tailored research and development.
By uniting stakeholders from governments, industry, and research institutions, this association can ensure a more robust response to areas of concern.
What we do
Effective and affordable veterinary vaccine development is equally crucial in today’s world, where they contribute significantly to the ultimate goal of ‘One Health’. The notable disparity in animal and human health is a concern.
I
Global manufacturing capacity
Enhance global manufacturing capacity by assessing current/spare manufacturing facilities, improving scalability, facilitating technology transfer, and providing training for human resources
II
Pooled procurement
Contribute to policy recommendations for implementing pooled procurement strategies, tiered pricing systems, and vaccine supply in LMICs* through collaboration with vaccine manufacturers and global institutions
III
Harmonisation for regulatory guidelines
AVVM’s networking platform will offer policy recommendations, collaborating with relevant stakeholders to harmonise regulatory guidelines. This involves prioritising pre-qualification systems, establishing priority lists, and defining Quality, Technical, and Target Product Profiles (QTPP) and Technical Requirements and Specifications (TRS) for vaccines
IV
Research & Development
AVVM will support translational projects through global funding, facilitate the development of central repository for strains, prioritise accelerated field trials, and foster innovation by integrating AI*, ML*, and CB* tools for accelerated development of novel veterinary vaccines for emerging and re-emerging pathogens